Name
Concurrent Breakfast | ZYNLONTA® (loncastuximab tesirine-lpyl), the First-and-Only CD19-Targeted ADC, for the Treatment of Adults with R/R DLBCL After Two or More Lines of Systemic Therapy
Date & Time
Thursday, April 28, 2022, 7:00 AM - 7:45 AM
Speakers
Description
Speaker: Suzanne R. Fanning, DO, University of South Carolina School of Medicine
Location Name
A706-A707